Related Experiment Video
Updated: Mar 26, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
[CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY]
Abstract:
Although cancer is a genetic disease, epigenetic alterations are involved in its initiation and progression. Previous studies showed that the introduction of endogenous small-sized, noncoding ribonucleotides including microRNA200c, -302s, and -369 resulted in the induction of cellular reprogramming. MicroRNA200c inhibits the epithelial-mesenchymal transition. MicroRNA302s induces the demethylation of the tumor suppressor gene promoter region, while microRNA369 changes cancer cell metabolism. These three types of microRNA induce cancer cellular reprogramming and modulate malignant phenotypes of human cancer cells. These results suggest that the appropriate delivery of functional small-sized ribonucleotides may be a novel approach to the treatment of human cancer.
Insights
Small noncoding ribonucleotides, including microRNAs, can reprogram cancer cells. These molecules offer a potential new strategy for treating human cancers by modulating malignant phenotypes.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Biology
Context:
- Cancer's genetic basis is complicated by epigenetic alterations influencing initiation and progression.
- Small noncoding ribonucleotides, specifically microRNAs, have been shown to induce cellular reprogramming.
- MicroRNA200c, -302s, and -369 are key players in these epigenetic modifications.
Purpose:
- To investigate the role of specific microRNAs (microRNA200c, -302s, -369) in cancer cellular reprogramming.
- To explore how these microRNAs modulate the malignant phenotypes of human cancer cells.
- To assess the therapeutic potential of delivering functional small-sized ribonucleotides for cancer treatment.
Summary:
- Introduction of microRNA200c, -302s, and -369 induces cellular reprogramming in cancer cells.
- MicroRNA200c inhibits epithelial-mesenchymal transition, a key process in cancer metastasis.
- MicroRNA302s promotes tumor suppressor gene expression by demethylating promoter regions.
- MicroRNA369 alters cancer cell metabolism, impacting tumor growth and survival.
Impact:
- These microRNAs reprogram cancer cells, suggesting a novel therapeutic avenue.
- Modulating cancer cell metabolism and epithelial-mesenchymal transition offers new targets for intervention.
- The findings support the development of small ribonucleotide-based therapies for human cancers.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistent Cancers
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
02:56Treatment Resistant Cancers